I-Exact Sciences Corp. namuhla imemezele ukuthi idatha evela ku-Rx ye-Positive Node, i-Endocrine Responsive Breast Cancer, noma i-RxPONDER, ukuhlolwa kwanyatheliswa ku-New England Journal of Medicine.i Ucwaningo, oluholwa yi-SWOG Cancer Research Network ezimele futhi luxhaswe yi- I-National Cancer Institute (NCI), ichaze ngempumelelo inzuzo yokwelashwa ngamakhemikhali ekuqaleni kwesigaba, iziguli ezinomdlavuza webele ezine-Oncotype DX Breast Recurrence Score® imiphumela engu-0 kuye ku-25. Imiphumela yokuqala evela ku-RxPONDER yabikwa ku-2020 San Antonio Breast Cancer. I-Symposium (SABCS). Okutholakele manje sekuqinisekisiwe kulokhu kushicilelwa okubuyekezwe ngontanga.
Okubalulekile, akukho nzuzo ye-chemotherapy eyabonwa kungakhathaliseki ukuthi ingakanani indawo ethintekile, ibanga lesimila noma usayizi. Kwabesifazane abangaphambi kokuya esikhathini abanama-node angu-1 kuya kwangu-3, inzuzo enkulu ye-chemotherapy ngokwezibalo yabonwa.
Cishe ingxenye eyodwa kwezintathu yeziguli ezitholwe zine-hormone receptor (HR)-positive, i-HER2-negative umdlavuza webele wangaphambi kwesikhathi zinethumba elisabalele kuma-lymph nodes. Iningi lalezi ziguli njengamanje zithola i-chemotherapyii nakuba cishe ama-85% azo anemiphumela ye-Recurrence Score ka-0 kuya ku-25.iii Ngaphezu kwalokho, cishe iziguli ezimbili kwezintathu zeziguli ezinomdlavuza webele ezitholakala emazingeni aphansi zi-postmenopausal.iv
Ngokusekelwe emiphumeleni ye-RxPONDER, i-National Comprehensive Cancer Network® (NCCN®)v ibuyekeze imihlahlandlela yayo yomdlavuza webele futhi yaqaphela ukuhlolwa kwe-Oncotype DX Breast Recurrence Score njengokuphela kokuhlolwa okungasetshenziswa ukubikezela inzuzo yokwelashwa ngamakhemikhali ekuqaleni kwebele. iziguli ezinomdlavuza ezinama-axillary lymph nodes angu-1 kuya ku-3, okuhlanganisa nama-micrometastases.vi Ukuhlolwa kwe-Oncotype DX manje kuwukuphela kokuhlolwa okubizwa ngokuthi "okuthandwayo" okunobufakazi obuphakeme kakhulu bobufakazi be-node-negative kanye ne-postmenopausal node-positive (1 kuya ku-3 amanodi amahle ) iziguli. Ngaphezu kwalokho, i-NCCN incoma ukucutshungulwa kokuhlolwa ukuze kuhlolwe ukubikezelwa kweziguli ezine-node-positive premenopausal ezidinga ukwelashwa ngamakhemikhali.
Esinye sezivivinyo ezinkulu kakhulu zomtholampilo kumdlavuza webele we-node-positive, i-HR-positive, i-HER2-negative ekuqaleni, i-RxPONDER ibhalise abesifazane abangaphezu kuka-5,000 abanama-node amathathu. Ucwaningo lweSigaba III obekulindelekile, olungahleliwe lwenziwa ezindaweni ezingama-632 emazweni ayisishiyagalolunye - e-United States, Canada, Mexico, Colombia, Ireland, France, Spain, South Korea naseSaudi Arabia. Abesifazane abanomphumela we-Recurrence Score ongu-0 kuye ku-25 bahlelwa ngokungahleliwe ekwelapheni nge-hormone therapy kuphela noma i-chemotherapy elandelwa ukwelapha ngamahomoni. Iziguli ezingahleliwe zahlukaniswa ngokusekelwe kumphumela wazo we-Recurrence Score, isimo sokunqamuka kokuya esikhathini kanye nohlobo lokuhlinzwa kwama-lymph node. Ukuhlaziya okwengeziwe nokulandelela isiguli okwengeziwe kuhlelwa abaphenyi be-SWOG.